Loren Data's SAM Daily™

FBO DAILY ISSUE OF AUGUST 25, 2002 FBO #0266
SOLICITATION NOTICE

66 -- High throughput Confocal Cell Imaging System

Notice Date

8/23/2002
 

Notice Type

Solicitation Notice
 

Contracting Office

Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Research Contracts Br., 6120 Executive Blvd. EPS Suite 600, Rockville, MD, 20852
 

ZIP Code

20852
 

Solicitation Number

NCI-20119-NG
 

Response Due

9/4/2002
 

Point of Contact

Malinda Holdcraft, Purchasing Agent, Phone (301) 402-4509, Fax (301) 402-4513, - Caren Rasmussen, Lead Contract Specialist, Phone (301) 402-4509, Fax (301) 402-4513,
 

E-Mail Address

holdcram@exchange.nih.gov, cr214i@nih.gov
 

Description

The National Cancer Institute (NCI) Advanced Technology Center (ATC) plans to procure the Atto Bioscience Pathway HT system from Atto Bioscience 15010 Broschart Road, Rockville, Maryland 20850. The supplies and services herein are commercial as defined in FAR Part 12, and this acquisition is being made in accordance with the test program for using simplified procedures for certain commercial items as authorized in FAR Part 13.5. The North American Industry Classification System code is 421450 and the business size standard is 100 employees. Researchers at the NCI Advanced Technology Center require the capability of studying living cells under a variety of conditions. These studies will include drug screening assays, cell microarrays, inhibitory small RNA (RNA1) studies, and so on. The Atto HT system fulfills these requirements at several levels. The unique spinning disk confocal capability allows high-throughput 3D structural analysis of samples and improves signal-to-noise ratios allowing the system to perform homogeneous assays. For drug screening this capability enables us the unique opportunity to analyze live cells upon drug addition using the on-stage liquid handling system contained within its climate controlled environmental chamber. The Pathway HT uses a proprietary optical path, which allows the 96 or 384 well plate to remain stationary while the high-resolution optics move independently from well to well. This important feature allows the researcher working with non-adherent cells to track individual cells throughout the duration of the assay. The flexibility of the two mercury arc lamps and binocular viewing allows full spectrum (340nm-700nm) real time viewing in cell arrays, tissue slides and tissue arrays. Finally, the Pathway HT software is capable of running the system in both a fully automated or manual mode, which is important for assay development and studies requiring 3D reconstruction of cellular events. Minimum Requirements: 1) full-spectrum capability (340nm to near-IR) using 16 excitation and 8 emission filters with independent dichroic mirror selection, 2) autofocus and auto cell identification/tracking, 3) switchable between confocal and widefield viewing modes, 4) capable of imaging both cells or tissues, 5) rapid multiple wavelength viewing, 6) kinetic or end-point measurements, 7) multiple plate slide and tissue array configurations (96, 384, chamber slides, microscope slides), 8) versatile liquid handling with mixing, 9) motorized high resolution X, Y, Z , and; 10) stationary stage with proprietary optical path. Atto Biosciences is the only source known to the NCI that can supply the Pathway HT system that allows the screening of live cells in a 96 or 384 well format. Also, cells can be analyzed continuously by a fluorescent confocal single-cell imaging system, giving the researcher the ability to measure multiple cellular events in real-time and in 3-Dimensional (3-D) space. The NCI ATC can use the Pathway HT system in drug screening assays, loss of function retroviral RNA1 studies and cell arrays. This is not a request for competitive quotations. However, if any interested party believes it can perform the above requirement, it may submit a statement of capabilities. All information furnished shall be in writing and must contain sufficient detail to allow NCI to determine if it can meet the above minimum specifications described herein. Capability statements must be received in the Contracting Office by 1:00 PM EDT (local Washington D.C. time) on September 4, 2002. If you have questions, please contact Malinda Holdcraft, Purchasing Agent via electronic mail at holdcram@excange.nih.gov or by fax at (301) 402-4513. A determination by the Government not to compete this proposed contract based upon responses to this notice is solely within the discretion of the Government. Information received shall be considered solely for the purpose of determining whether to conduct a competitive procurement. No collect calls will be accepted.
 

Place of Performance

Address: NIH/NCI, 9000 Rockville Pike, Bethesda, MD 20892

Zip Code: 20892

Country: USA
 

Record

SN00148645-W 20020825/020823213247 (fbodaily.com)
 

Source

FedBizOpps.gov Link to This Notice
(may not be valid after Archive Date)

---

| FSG Index  |  This Issue's Index  |  Today's FBO Daily Index Page |